DNA damage induced by a quinoxaline 1,4-di-Af-oxide derivative (hypoxic selective agent) in Caco-2 cells evaluated by the comet assay

Mutagenesis

Volumn 20, Issue 3, 2005, Pages 165-171

  Azqueta, Amaia ^a   Pachón, Gisela ^b   Cascante, Marta ^b   Creppy, Edmond E ^c   López De Cerain, Adela ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

7 CHLORO 3 [[(N,N DIMETHYLAMINO)PROPYL]AMINO] 2 QUINOXALINECARBONITRILE 1,4 DI N OXIDE HYDROCHLORIDE; FLUORESCEIN ISOTHIOCYANATE; LIPOCORTIN 5; QUINOXALINE DERIVATIVE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL COUNT; CELL NUCLEUS; CELL PROLIFERATION; CELL STRAIN CACO 2; COMET ASSAY; DNA DAMAGE; DNA REPAIR; DRUG EFFECT; DRUG MECHANISM; FLOW CYTOMETRY; GENOTOXICITY; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; OXYGENATION; PRIORITY JOURNAL; TOXICITY;

APOPTOSIS; CACO-2 CELLS; CELL HYPOXIA; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; COMET ASSAY; DNA; DNA DAMAGE; DNA REPAIR; HUMANS; MUTAGENS; OXIDATION-REDUCTION; QUINOXALINES;

EID: 19544376104     PISSN: 02678357     EISSN: None     Source Type: Journal    
DOI: 10.1093/mutage/gei023     Document Type: Article

References (46)

1. Denny,W.A. (2000) The role of hypoxia-activated prodrugs in cancer therapy. Oncology, 1, 25-29.
2. Denny,W.A. (2001) Prodrug strategies in cancer therapy, Eur. J. Med. Chem., 36, 577-595.
3. Kennedy,K.A., Teicher,B.A., Rockwell,S. and Sartorelli,A.C. (1980) The hyponic tumor cell: a target for selective cancer chemotherapy. Biochem. Pharmacol., 29, 1-8.
4. Durand,R.E. and Sham,E. (1998) The lifetime of hypoxic human tumor cells. Int. J. Radiat. Oncol. Biol. Phys., 42, 711-715.
5. Guppy,M, (2002) The hypoxic core: a possible answer to the cancer paradox. Biochem. Biophys. Res. Commun., 299, 676-680.
6. Brown,J.M. and Giaccia,AJ. (1998) The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res., 58, 1408-1416.
7. Brown,J.M. (1999) The hypoxic cell: a target for selective cancer therapy-eighteenth Bruce F.Cain memorial award lecture, Cancer Res., 59, 5863-5870.
8. Brown,J.M. (2000) Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol. Med. Today, 6, 157-161.
9. Villa,M.A. (2001) La radioterapia en relación con la hipoxia tumoral y la anemia. Radiobiología, 1, 7-8
10. Wouters,B.G., Weppler,S.A., Koritzinsky,M., Landuyt,W., Nuyts,S., Theys,J., Chiu,R.K. and Lambin,P. (2002) Hypoxia as a target for combined modality treatments, Eur. J. Cancer, 38, 240-257.
11. Graeber,T.G., Osmanian,C., Jacks,T., Housman,D.E., Koch,CJ., Lowe,S.W. and Giaccia,A.J. (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours, Nature, 379, 88-91.
12. Hockel,M., Schlenger,K., Hockel,S. and Vaupel,P. (1999) Hypoxie cervical cancers with low apoptotic index are highly aggressive. Cancer Res., 59, 4525-4528.
13. Hockel,M., Schlenger,K., Aral,B., Mitze,M., Schaffer,U. and Vaupel,P. (1996) Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res., 56, 4509-4515.
14. Nordsmark,M., Overgaard,M. and Overgaard,J. (1996) Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother. Oncol., 41, 31-39.
15. Brizel,D.M., Dodge,R.K., Clough,R.W. and Dewhirst,M.W. (1999) Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome, Radiother. Oncol., 53, 113-117.
16. Fyles,A.W., Milosevic,M., Wong,R. et al. (1998) Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother. Oncol., 48, 149-156.
17. 2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix, Radiother. Oncol., 53, 99-104.
18. Feldmann,H.J. (2001) Oxygenation of human tumors-implications for combined therapy. Lung Cancer, Suppl. 1, S77-S83.
19. Evans,S.M. and Koch,C.J. (2003) Prognostic significance of tumor oxygenation in humans. Cancer Lett., 195, 1-16.
20. Lin,A.J., Cosby,L.A., Shansky,C.W. and Sartorelli,A.C. (1972) Potential bioreductive alkylating agents. 1. Benzoquinone derivatives. J. Med. Chem., 15, 1247-1252.
21. Rauth,A.M., Melo,T. and Misra,V. (1998) Bioreductive therapies: an overview of drags and their mechanisms of action. Int. J. Radiat. Oncol., Biol. Phys., 42, 755-762.
22. Brown,J.M. and Koong,A.J. (1991) Therapeutic advantage of hypoxic cells in tumors: a theoretical study. J. Natl Cancer Inst., 83, 178-185.
23. Kovacs,M.S., Hocking,D.J., Evans,J.W., Siim,B.G., Wouters,B.G. and Brown,J.M. (1999) Cisplatin anti-tumor potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin, Br. J. Cancer, 80, 1245-1251.
24. Zeman,E.M., Brown,J.M., Lemmon,M.J., Hirst,V.K. and Lee,W.W. (1986) SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int. J. Radiat. Oncol. Biol. Phys., 12, 1239-1242.
25. Elwell,J.H., Siim,B.G., Evans,J.W. and Brown,J.M, (1997) Adaptation of human tumour cells to tirapazamine under aerobic conditions-implications of increased antioxidant enzyme activity to mechanism of aerobic toxicity. Biochem. Pharmacol., 54, 249-257.
26. Biedermann,K.A., Wang,J., Graham,R.P. and Brown,J.M. (1991) SR4233 cytotoxicity and metabolism in DNA repair-competent and repair-deficient cell cultures. Br. J. Cancer, 63, 358-362.
27. Siim,B.G., van Zijl,P.L. and Brown,J.M. (1996) Tirapazamine-induced DNA damage measured using the comet assay correlates with toxicity towards hypoxic tumour cells in vitro. Br. J. Cancer, 73, 952-960.
28. Kotandeniya,D., Ganley,B. and Gates,K.S. (2002) Oxidative DNA base damage by the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine). Bioorg. Med. Chem. Lett., 12, 2325-2329.
29. Wang,J., Biedermann,K.A. and Brown,J.M. (1992) Repair of DNA and chromosome breaks in cells exposed to SR-4233 under hypoxia or to ionizing radiation. Cancer Res., 52, 4473-4477.
30. Daniels,J.S. and Gates,K.S. (1998) Direct evidence for bimodal DNA damage induced by tirapazamine. Chem. Res. Toxicol., 11, 1254-1257.
31. Delahoussaye,Y.M., Hay,M.P., Pruijn,F.B., Denny,W.A. and Brown,J.M. (2003) Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting. Biochem. Pharmacol., 65, 1807-1815.
32. Monge,A., Martinez-Crespo,F.J., López de Cerain,A. et al. (1995) Hypoxia-selective agents derived from 2-quinoxalinecarbonitrile 1,4-di-N-oxides, J. Med. Chem., 38, 4488-4494.
33. Azqueta,A., Pachon,G., Cascante,M., Crcppy,E., Monge,A. and Lopez de Cerain,A. (2004) Selective toxicity of a quinoxaline 1,4-di-N-oxide derivative in human tumoral cell lines. Arzneim. Forsch./Drug Res., 3, 177-182.
34. Henessey,T.D. and Edwards,J.R. (1972) Antibacterial properties of quindoxin. New growth-promoting agent. Vet. Rec., 90, 187-191.
35. Suter,W., Rosselet,A. and Knüsel,F. (1978) Mode of action of quindoxin and substituted quinoxaline-di-N-oxides on Escherichia coli. Antimicrob. Agents Chemother., 13, 770-783.
36. Voogd,C.E., Van der Stel,J.J. and Jacobs,J.J. (1980) The mutagenic action of quindoxin, carbadox, olaquindox and some other N-oxides on bacteria and yeast. Mutat. Res., 78, 233-242.
37. Nunoshiba,T. and Nishioka,H. (1989) Genotoxicity of quinoxaline 1,4-dioxide derivatives in Escherichia coli and Salmonella typhimurium. Mutat. Res., 217, 203-209.
38. Tucker, M.J. (1975) Carcinogenic action of quinoxaline 1,4-dioxide in rats. J. Natl Cancer Inst., 55, 137-146.
39. Ganley,B., Chowdhury,G., Bhansali,J., Daniels,J.S. and Gates,K.S. (2001) Redox-activated, hypoxia-selective DNA cleavage by quinoxaline 1,4-di-N-oxides. Bioorg. Med. Chem., 9, 2395-2401.
40. Zamalloa,E., Aldana,I., Bachiller,C.M. and Monge,A. (1997) Physicochemical properties and stability of the new hypoxia-selective agent 7-chloro-3-[[(N,N,-dimethylamino)propyl]amino]-2-quinoxalinecarbonitrile 1,4-di-N-oxide hydrochloride. Arzneim. Forsch./Drug Res., 47, 873-878.
41. Pappenheimer,A.M. (1917) Experimental studies upon lymphocytes: I. The reactions of lymphocytes under various experimental conditions, J. Exp. Med., 25, 633-650.
42. Singh,N.P., McCoy,M.T., Tice,R.R. and Schneider,E.L. (1988) A simple technique for quantitation of low levels of DNA damage in individual cells. Exp. Cell Res., 175, 184-191.
43. Tice,R.R., Agurell,E., Anderson,D., Burlinson,B., Hartmann,A., Kobayashi,H., Miyamae,Y., Rojas,E., Ryu,J.C. and Sasaki,Y.F. (2000) Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing, Environ. Mol. Mutagen., 35, 206-221.
44. Frankenberg-Schwager,M, (1989) Review of repair kinetics for DNA damage induced in eukaryotic cells in vitro by ionizing radiation. Radiother. Oncol., 14, 307-320.
45. Collins,A.R., Al-guo,M. and Duthie,S.J. (1995) The kinetics of repair of oxidative DNA damage (strand breaks and oxidised pyrimidines) in human cells. Mutat. Res., 336, 69-77.
46. Kobayashi,H., Sugiyama,C., Morikawa,Y., Hayashi,M. and Sofuni,T. (1995) A comparison between manual microscopic analysis and computerized image analysis in the single cell gel electrophoresis assay. MMS Commun., 3, 103-115.